Didymin

Isosakuranetin, an O-methylated flavonoid, is the 4'-methoxy derivative of naringenin, a flavanone. Didymin, a disaccharide of isosakuranetin, occurs in sweet orange, blood orange, and mandarin. The compound is assigned CAS registry number 14259-47-3 and has a molecular formula of C₂₈H₃₄O₁₄ with a molecular weight of 594.57 g/mol.

1.2 Physical and Chemical Properties

Didymin is a dietary flavanone glycoside distributed in plants such as citrus and campanula. It is a white needle-like compound that has a higher solubility in methanol than water, and it should be stored in a cool, dark place. Core unit modification, including hydroxylation, methylation, prenylation, alkylation, and glycosylation, greatly amplifies the number of these flavonoids. Flavonoid glycosides are natural molecules in which flavonoids are bonded to sugar via a glycosidic bond. They are a dominant existential form of flavonoids and a common component of many plants.

1.3 Natural Sources and Botanical Origin

Didymin is commonly found in citrus fruits and campanula, including mandarin, bergamot, orange, Origanum, and Vulgare Duanxueliu. Didymin is found in various citrus fruits such as oranges, lemons, mandarin, bergamot, grapefruit, chachi fruit, and citrus juices.

Didymin (DID) is a natural compound and the major polyphenol of Monarda didyma L., a herb of the mint family (Lamiaceae). The genus name Monarda didyma is the source of the compound's common name. Additionally, didymin is also rich in Clinopodium chinense, also known as "Duanxueliu," which is a traditional Chinese herb for the treatment of hematuria, skin trauma, influenza, and allergic dermatitis.

Reported quantitative data from citrus fruits indicate significant natural concentrations: "Valencia" oranges contain 1.62 mg/g of didymin. Didymin ranks fourth among health-promoting flavonoids in Rio Red grapefruit, with a content of 2.49 ± 0.10 mg/g.

Origanum vulgare L. is a traditional Chinese herb with a strong hepatoprotective effect, and didymin has been isolated from and identified as a constituent of this herb.

1.4 Common Forms and Preparations

Due to its high content in citrus and easy extraction, didymin has been recognized as an inexpensive, safe, and effective oral drug that does not cause toxicity to normal tissues. In research settings, didymin is commercially available in highly purified form (greater than 99% purity by HPLC) and is typically handled as a dry powder dissolved in organic solvents such as methanol or DMSO for in vitro work, or formulated for oral administration in animal studies. Chenpi, one kind of dried peel of citrus fruits, has traditionally been utilized as a medicinal herb for liver diseases, and didymin is a newly identified oral bioactive dietary flavonoid glycoside derived from Chenpi.

Research into delivery systems has explored specialized formulations. Didymin is one of the dietary glycosides commonly found in mandarin, bergamot, orange, and other fruits or plants, and has long been recognized as a safe, effective, and inexpensive dietary supplement.

2. Traditional and Historical Use

2.1 East and Southeast Asian Traditions

Traditionally, this flavonoid has long been used in Asian countries as a dietary antioxidant. Its primary vehicle of traditional use was the consumption of citrus fruits and citrus-derived preparations — peels, dried fruit rinds, and decoctions — that have formed part of culinary and medicinal culture across China, Japan, and other Asian societies for millennia. The dried peel of citrus fruits (known as Chenpi in Chinese traditional medicine) and preparations of Clinopodium chinense (Duanxueliu) were both vehicles of didymin intake in practice, even before the compound was chemically identified.

Didymin is rich in Clinopodium chinense, also known as "Duanxueliu," which is a traditional Chinese herb for the treatment of hematuria, skin trauma, influenza, and allergic dermatitis. This herb has been used for these purposes within the framework of Traditional Chinese Medicine (TCM).

2.2 Mexican Traditional Medicine

The antinociceptive and sedative effects of an aqueous extract of Clinopodium mexicanum Benth Govaerts (Lamiaceae), known as "toronjil de monte" (hill's hyssop), a medicinal plant used as a tranquilizer in Mexican traditional medicine, have been reported. Neoponcirin (synonym: isosakuranetin-7-O-rutinoside and didymin) is one of the major constituents of a complex mixture of flavone and flavanone glycosides present in the aqueous and methanol extracts of this medicinal plant.

Leaves of Clinopodium mexicanum have been used in Mexican traditional medicine for sleeplessness, analgesic, and sedative treatment. The aqueous extracts of leaves treated mice produced prolonged sleeping time, sedative effect, and delayed the onset of seizures induced by pentylenetetrazole. Chemical analysis revealed that flavonoid glycosides, including didymin, poncirin, and isonaringenin, are the three main components of the aqueous extract. Among them, didymin is the leading constituent of the complex mixture of flavonoids present in the active extracts of Clinopodium mexicanum.

2(S)-neoponcirin (NEO) is a constituent of Clinopodium mexicanum, which is used in traditional Mexican herbal medicine for its tranquilizing and analgesic properties.

3. Key Constituents, Structural Features, and Mechanisms of Action

3.1 Structural Basis of Bioactivity

Didymin is a flavanone glycoside in which the flavanone aglycone isosakuranetin — itself the 4'-O-methyl ether of naringenin — carries a rutinose (6-O-α-l-rhamnosyl-β-d-glucosyl) disaccharide at C-7. This glycosidic linkage confers water-assisted oral bioactivity and differentiates it structurally from its neohesperidoside isomer poncirin, which has the same aglycone but a different sugar linkage (neohesperidose instead of rutinose). Flavonoid glycosides are natural molecules in which flavonoids are bonded to sugar via a glycosidic bond, and they are a dominant existential form of flavonoids and a common component of many plants.

3.2 Antioxidant Activity

Didymin, a dietary flavonoid glycoside from citrus fruits, possesses antioxidant properties. The compound scavenges reactive oxygen species (ROS) and modulates endogenous antioxidant enzymes. A previous study showed that didymin possessed the neuroprotective property of scavenging free radicals and the capability of rescuing the neuronal cells from oxidative damage in neuronal cells after hydrogen peroxide-induced injury. In liver models, treatment with didymin isolated from Origanum vulgare significantly reduced CYP2E1 activity, lipid peroxidation level, ROS generation, NO production, and pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β) in liver tissues and RAW 264.7 cells, but enhanced the hepatic antioxidative enzyme activities.

3.3 Anti-Inflammatory Mechanisms

Didymin regulates various important signaling molecules, such as suppressing the MAPK/NF-κB signaling pathway and TLR4/NF-κB and PI3K/Akt pathways, as well as switching M1-like toward M2-like macrophage polarization. A recent study suggested that didymin treatment significantly attenuated MPO activity and neutrophil infiltration and converted pro-inflammatory M1-like to the anti-inflammatory M2-like macrophage phenotype, thereby alleviating the clinical symptoms of colitis.

In acute liver injury, didymin can exert an anti-inflammatory effect and alleviate hepatic injury by upregulating the expression of Raf kinase inhibitor protein (RKIP).

3.4 Anticancer Mechanisms

Multiple complementary mechanisms underlie didymin's preclinical anticancer activity. In non-small-cell lung cancer (NSCLC) cells, the results showed that didymin-induced apoptosis of A549 and H460 cells without mediation of p53 and p21/WAF1, suggesting that the Fas/Fas ligand apoptotic system is the main pathway of didymin-mediated apoptosis of A549 and H460 cells.

In neuroblastoma models, didymin effectively inhibited proliferation and induced apoptosis irrespective of p53 status in neuroblastomas; didymin downregulated phosphoinositide 3-kinase, pAkt, Akt, vimentin, and upregulated RKIP levels. Didymin upregulates RKIP levels and inhibits N-Myc at the protein, mRNA, and transcriptional level. Thus, the anticancer potential of didymin likely arises from its multi-specific anticancer mechanism of action.

Didymin caused significant G2/M phase arrest in CHLA-90 (p53-mutant) and SMS-KCNR (p53 wild-type) neuroblastoma cells, suggesting the inhibition of cell cycle as an additional mechanism for the anti-proliferative effects of didymin. Western blot of didymin-treated neuroblastoma cells revealed decreases in cyclin B1, cyclin D1, and CDK4.

Didymin decreases the proliferation of NB cells via the downregulation of the phosphoinositide 3-kinase (PI3K) and Akt pathways. Furthermore, proto-oncogene N-Myc transcription was inhibited by didymin.

3.5 Anti-Diabetic and Metabolic Mechanisms

The anti-diabetic potential of didymin was evaluated via inhibition of α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), rat lens aldose reductase (RLAR), human recombinant aldose reductase (HRAR), and advanced glycation end-product (AGE) formation inhibitory assays. Didymin strongly inhibited PTP1B, α-glucosidase, HRAR, RLAR, and AGE in the corresponding assays. Kinetic study revealed that didymin exhibited a mixed type inhibition against α-glucosidase and HRAR, while it competitively inhibited PTP1B and RLAR.

3.6 Neuroprotective Mechanisms

The literature suggests that flavonoids exert potential medicinal functions including suppressing excitotoxicity, Ca²⁺ overloading, oxidative stress, inflammation, thrombin's cellular toxicity, different types of programmed cell deaths, and protecting the blood-brain barrier, as well as promoting neurogenesis in the recovery stage following ischemic stroke. Didymin participates in these neuroprotective activities through its combined antioxidant and anti-inflammatory actions as described in experimental models.

In experimental intracerebral hemorrhage, inflammatory response with extensive microglial activation and aberrant neutrophil infiltration in the ipsilateral cortex was induced during the acute stage. Didymin treatment evidently mitigated microglial activation and neutrophil infiltration and inhibited the release of inflammatory cytokines such as IL-1β, TNF-α, and MPO.

4. Scientific Evidence by Area of Use

4.1 Oncology

4.1.1 Non-Small-Cell Lung Cancer (NSCLC)

A published study first investigated the anticancer effect of didymin in human non-small-cell lung cancer A549 and H460 cells. To identify the anticancer mechanism of didymin, the researchers assayed its effect on apoptosis, cell cycle distribution, and levels of p53, p21/WAF1, Fas/APO-1 receptor, and Fas ligand. Notably, a novel chemotherapeutic effect for the treatment of non-small-cell lung cancer was supported by animal studies showing that didymin delayed tumor growth in nude mice.

Evidence strength: Preclinical only (in vitro cell line studies and rodent xenograft models). No human clinical trials have been reported for this indication.

4.1.2 Neuroblastoma

Didymin is a citrus-derived natural compound that kills p53 wild-type as well as drug-resistant p53-mutant neuroblastoma cells in culture. In addition, orally administered didymin causes regression of neuroblastoma xenografts in mouse models.

Didymin inhibited N-Myc as confirmed at protein, mRNA, and transcriptional level by promoter-reporter assays. High-performance liquid chromatography analysis of didymin-treated (2 mg/kg body weight) mice serum revealed effective oral absorption with free didymin concentration of 2.1 μmol/L. Further in vivo mice xenograft studies revealed that didymin-treated (2 mg/kg body weight) animals had significant reductions in tumor size compared with controls.

Didymin strongly inhibited the proliferation (Ki67) and angiogenesis (CD31) markers, as well as N-Myc expression, as revealed by histopathologic examination of paraffin-embedded sections of resected tumors.

Such studies would benefit the rational development of didymin formulations as well as personalized combinations of anticancer drugs with didymin to achieve better clinical response in patients with differing tumor genotypes and drug-sensitivity profiles. The findings regarding the novel, safe, and palatable dietary flavonoid didymin have revealed its anticancer properties irrespective of N-Myc amplification and p53 mutation status in NB. Thus, didymin represents a highly promising flavonoid with potential clinical significance to effectively prevent the incidence of NB and as an innovative approach for new treatment strategies.

RKIP is a Raf-inhibitory protein that regulates MYCN activation, is transcriptionally upregulated by didymin, and appears to play a key role in the anti-neuroblastoma actions of didymin. Didymin overcomes drug-resistance in p53-mutant neuroblastoma through RKIP-mediated inhibition of MYCN and its effects on GRK2, PKCs, Let-7 micro-RNA, and clathrin-dependent endocytosis by Raf-dependent and -independent mechanisms.

Evidence strength: Preclinical only — in vitro and xenograft mouse model studies. No human clinical trials reported. Neuroblastoma research represents the most mechanistically detailed body of didymin literature.

4.1.3 Other Cancer Types

Emerging data also present the potential therapeutic application of dietary flavonoid glycoside didymin against cancer, neurological diseases, liver diseases, cardiovascular diseases, and other diseases. Studies have demonstrated that didymin can inhibit the growth of neuroblastoma, lung, and colon cancer cells through mechanisms involving the PI3K/Akt/NF-κB signaling pathways.

Evidence strength: Preclinical only (cell line and animal models). All anticancer evidence for didymin as of the available literature is preliminary and restricted to laboratory settings.

4.2 Neurological and Central Nervous System Effects

4.2.1 Neuroprotection

Studies have confirmed that didymin shows promising biological activities including antioxidant and neuroprotective effects. In experimental models of oxidative neuronal damage, didymin possessed the neuroprotective property of scavenging free radicals and the capability of rescuing neuronal cells from oxidative damage after hydrogen peroxide-induced injury.

4.2.2 Intracerebral Hemorrhage

Didymin, a dietary citrus flavonoid, has been previously reported to possess multiple pharmacological activities including anticancer, antioxidant, anti-inflammation, neuroprotective, hepatoprotective, and cardiovascular activities. In a published study of experimental intracerebral hemorrhage (ICH), didymin treatment mitigated microglial activation and neutrophil infiltration and inhibited the release of inflammatory cytokines such as IL-1β, TNF-α, and MPO.

Evidence strength: Preclinical rodent models. No human trials identified.

4.2.3 Anxiolytic and Antinociceptive Effects

2(S)-neoponcirin is a constituent from Clinopodium mexicanum, which is used in traditional Mexican herbal medicine for its tranquilizing and analgesic properties. This study investigated the anxiolytic-like, sedative and antinociceptive effects of neoponcirin (didymin) in several mice models. The anxiolytic-like effect was evaluated in the hole-board and Open Field Tests; sedative effect was evaluated in sleeping time induced by sodium pentobarbital, and antinociceptive actions were measured in the hot plate test. To evaluate if the GABA receptor could be involved in the anxiolytic-like effect produced by neoponcirin/didymin, the effects produced by co-administration of neoponcirin plus muscimol and neoponcirin plus picrotoxin were evaluated in the hole-board test.

Evidence strength: Preclinical (rodent behavioral models). These studies provide mechanistic plausibility for the traditional sedative/analgesic uses of the plant but no human clinical evidence exists.

4.3 Hepatoprotective (Liver) Effects

4.3.1 Acute Liver Injury

A flavone was isolated from Origanum vulgare and identified as didymin. The protective effect and mechanism of this compound on acute liver injury was then assessed in vivo and in vitro. The results showed that it significantly alleviated CCl4-induced liver injury in mice and markedly decreased serum ALT and AST activities.

4.3.2 Liver Fibrosis

This study investigated the effects and underlying mechanisms of didymin on liver injury and fibrosis, evaluating whether it was the pharmacodynamic material basis of Origanum vulgare L. Mice were injected with CCl4 for 10 weeks to induce liver fibrosis, followed by didymin treatment for 6 weeks. Biochemical analysis and histopathological examinations were conducted to evaluate the therapeutic effects of didymin in alleviating fibrosis, and the possible mechanisms were predicted by transcriptomics and then verified by multiple relevant examinations. The pharmacodynamic experiments indicated that didymin significantly attenuated CCl4-induced hepatic injury and fibrogenesis, as evidenced by ameliorative pathological tissue, low transaminase activity, and decreased fibrosis-related markers.

4.3.3 Metabolic-Dysfunction Associated Fatty Liver Disease (MAFLD)

Researchers investigated the therapeutic potential of didymin as an anti-MAFLD drug and elucidated its underlying mechanisms. High-fat diet (HFD)-induced MAFLD mice and alpha mouse liver 12 (AML12) cells were utilized to evaluate the effects and mechanisms of didymin in the treatment of MAFLD. In this study, the hepatoprotective effects of didymin against MAFLD were investigated in both in vitro AML12 cells and in vivo HFD-induced MAFLD mice. It was demonstrated that didymin ameliorated mitochondrial function, augmented lipophagy, and attenuated apoptosis by enhancing the expression and deacylation activity of Sirt1.

Evidence strength: Preclinical (in vitro and rodent models). No human clinical data exist for any hepatic indication.

4.4 Cardiovascular Effects

4.4.1 Cardioprotection Against Doxorubicin-Induced Toxicity

Didymin attenuates doxorubicin-induced cardiotoxicity by inhibiting oxidative stress. A published study in Chin Herb Med (2021) by Chen et al. specifically examined this cardioprotective action at a preclinical level, demonstrating that didymin suppressed oxidative stress pathways triggered by the anthracycline chemotherapeutic agent doxorubicin. Didymin is reported to show protective effects against doxorubicin-prompted cardiac damage by suppressing oxidative stress.

4.4.2 Additional Cardiovascular Research

Recent studies have revealed that didymin displays anti-nociceptive, anti-oxidant, neuroprotective, anti-inflammatory, and cardioprotective activities. The cardiovascular interest in didymin centers on its ability to reduce oxidative stress in cardiac tissue, modulate inflammatory cytokines relevant to cardiac remodeling, and potentially protect vascular endothelial function.

Evidence strength: Preclinical (in vitro cardiomyocyte and rodent models). No controlled human studies identified.

4.5 Metabolic and Endocrine Effects

4.5.1 Anti-Diabetic Activity

Didymin is a naturally occurring orally active flavonoid glycoside found in various citrus fruits, which has been previously reported to possess a wide variety of pharmacological activities including anticancer, antioxidant, antinociceptive, neuroprotective, hepatoprotective, inflammatory, and cardiovascular. With respect to diabetes specifically, the anti-diabetic potential of didymin was evaluated via inhibition of α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), rat lens aldose reductase (RLAR), human recombinant AR (HRAR), and advanced glycation end-product (AGE) formation inhibitory assays.

4.5.2 Pancreatic Beta Cell Protection

Prolonged exposure to plasma free fatty acids leads to impaired glucose tolerance (IGT) which can progress to type 2 diabetes (T2D) in the absence of timely and effective interventions. High-fat diet (HFD) leads to chronic inflammation and oxidative stress, impairing pancreatic beta cell function. While didymin, a flavonoid glycoside derived from citrus fruits, has beneficial effects on inflammation dysfunction, its specific role in HFD-induced IGT remains yet to be elucidated. This study aimed to investigate the protective effects of didymin on pancreatic beta cells. HFD-induced IGT mice and INS-1 cells were used to explore the effect and mechanism of didymin in alleviating IGT.

Evidence strength: All anti-diabetic evidence is preclinical (enzyme inhibition assays, cell culture, and rodent models). No human clinical trials have been reported for metabolic indications.

4.6 Anti-Inflammatory Effects (Gastrointestinal)

A study suggested that didymin treatment significantly attenuated MPO activity and neutrophil infiltration and converted pro-inflammatory M1-like to the anti-inflammatory M2-like macrophage phenotype, thereby alleviating the clinical symptoms of colitis. Research involving total flavonoids from Clinopodium chinense, the plant from which didymin is the major constituent, has also examined cardioprotective and hepatoprotective effects in rodent models.

5. Pharmacokinetics, Bioavailability, and Delivery

5.1 Oral Bioavailability

Didymin is a commercially available dietary flavonoid glycoside derived from citrus fruits and has high therapeutic efficacy. As a glycoside, it is subject to hydrolysis in the gastrointestinal tract prior to absorption, analogous to other flavanone glycosides. High-performance liquid chromatography analysis of didymin-treated (2 mg/kg body weight) mice serum revealed effective oral absorption with free didymin concentration of 2.1 μmol/L, demonstrating that the compound does reach systemic circulation after oral dosing in preclinical models.

In terms of solubility — a key determinant of bioavailability — didymin has a higher solubility in methanol than water, indicating limited aqueous solubility, which is characteristic of many flavonoid glycosides and may constrain absorption from aqueous gastrointestinal environments.

5.2 In Vivo Dosages Reported in Preclinical Studies

The dosages used in published animal studies provide the only available quantitative dosing data, as no human clinical dosing has been established:

• In neuroblastoma xenograft studies, didymin was administered at 2 mg/kg body weight; HPLC analysis of treated mice serum revealed effective oral absorption with free didymin concentration of 2.1 μmol/L, and animals showed significant reductions in tumor size compared with controls.

No standardized human dosage form or dose range for didymin as a dietary supplement has been established in the peer-reviewed literature. All dosage information in the literature is derived from in vitro or animal experiments and cannot be extrapolated to human use.

5.3 Formulation Research

Didymin is one of the dietary glycosides commonly found in mandarin, bergamot, orange, and other fruits or plants. It has long been recognized as a safe, effective, and inexpensive dietary supplement. Recent advances in pharmacological activities of didymin and related signaling molecules in many diseases have been summarized. The compound's limited water solubility has motivated research into improved delivery systems; however, published nanoparticle or advanced-formulation studies specifically and exclusively focused on didymin are limited, and the bulk of the literature uses simple dissolved preparations in preclinical models.

6. Safety and Toxicology

6.1 General Safety Profile

Due to its high content in citrus and easy extraction, didymin has been recognized as an inexpensive, safe, and effective oral drug that does not cause toxicity to normal tissues. Overall, didymin appears to be a palatable, well-tolerated, and effective alternative to conventional treatment approaches for NB in preclinical settings.

Didymin is a citrus-derived natural compound that kills p53 wild-type as well as drug-resistant p53-mutant neuroblastoma cells in culture. In addition, orally administered didymin causes regression of neuroblastoma xenografts in mouse models, and critically, investigations found no toxicity to non-malignant cells. Orally administered didymin causes regression of neuroblastoma xenografts in mouse models, without toxicity to non-malignant cells, neural tissues, or neural stem cells.

6.2 Absence of Human Toxicology Data

There are no published human clinical trials or formal Phase I safety studies that have characterized the safety, tolerability, maximum tolerated dose, or adverse effect profile of didymin in humans. All safety characterizations in the current literature are derived from in vitro and preclinical animal experiments. Recent studies have provided newer insights into this pleiotropic compound, which could regulate multiple biological activities of many important signaling molecules in health and disease, but these insights are not yet supported by human safety data.

6.3 Reproductive Toxicology

Published literature has examined didymin in the context of environmental toxicant protection. Studies have investigated the protective effect of didymin against reproductive toxicity induced by dioxin compounds (TCDD) in male rat models, though formal reproductive safety assessment of didymin itself has not been published in the peer-reviewed sources reviewed here.

6.4 Interaction Potential

Didymin regulates various important signaling molecules, such as suppressing the MAPK/NF-κB signaling pathway and TLR4/NF-κB and PI3K/Akt pathways. Given its activity on these broad signaling pathways, theoretical interactions with pharmaceutical agents that similarly target PI3K/Akt, NF-κB, or MAPK pathways are plausible, but no peer-reviewed pharmacokinetic drug-drug interaction studies for didymin have been identified in the available literature.

Recent preclinical research has explored didymin's potential anti-cancer properties and its ability to mitigate side effects associated with chemotherapy. Scientific studies, mostly in vitro and in vivo animal models, indicate that didymin may exert anti-tumor effects by inducing apoptosis, inhibiting cancer cell proliferation, and modulating oxidative stress pathways. The co-administration of didymin with chemotherapeutic agents (e.g., doxorubicin) has been examined in preclinical settings for cardioprotective synergy, though clinical data to establish safety or efficacy of such combinations are absent.

7. Current State of Evidence and Research Gaps

The therapeutic potential of didymin with anti-oxidant activity in promoting health is drawing more attention in recent years. With intensive pharmacological study results, didymin seems to have more important prospects other than a pure natural antioxidant.

Recent studies have provided newer insights into this pleiotropic compound, which could regulate multiple biological activities of many important signaling molecules in health and disease. Emerging data also present the potential therapeutic application of dietary flavonoid glycoside didymin against cancer, neurological diseases, liver diseases, cardiovascular diseases, and other diseases.

The totality of published scientific evidence for didymin, while demonstrating diverse and mechanistically coherent preclinical activity, remains entirely at the preclinical stage. The evidence is still preliminary and largely based on laboratory (in vitro) and animal studies. No registered or completed human clinical trials for any indication have been identified in the reviewed literature. Key research gaps include: human pharmacokinetic and bioavailability studies, dose-finding and Phase I safety trials, standardized formulations, and randomized controlled trials for any of the proposed therapeutic applications.

Such studies would benefit the rational development of didymin formulations as well as personalized combinations of anticancer drugs with didymin to achieve better clinical response in patients with differing tumor genotypes and drug-sensitivity profiles.

References

• Yao Q, Lin MT, Zhu YD, Xu HL, Zhao YZ. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin. Molecules. 2018;23(10):2547. PubMed PMID: 30301216.
• Yao Q et al. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin. PMC Full Text. PMC6222367.
• Singhal J, Nagaprashantha LD, et al. Didymin: an orally active citrus flavonoid for targeting neuroblastoma. Oncotarget. 2017. PubMed PMID: 28187004.
• Singhal J et al. Didymin: an orally active citrus flavonoid for targeting neuroblastoma. PMC Full Text. PMC5438742.
• Hung JY, Hsu YL, Ko YC, et al. Didymin, a dietary flavonoid glycoside from citrus fruits, induces Fas-mediated apoptotic pathway in human non-small-cell lung cancer cells in vitro and in vivo. Lung Cancer. 2010;68(3):366-74. PubMed PMID: 19733932.
• Singhal J, Nagaprashantha LD, et al. Didymin Induces Apoptosis by Inhibiting N-Myc and Upregulating RKIP in Neuroblastoma. PMC Full Text. PMC3294094.
• Singhal J et al. Didymin Induces Apoptosis by Inhibiting N-Myc and Upregulating RKIP in Neuroblastoma. Cancer Prevention Research. 2012;5(3):473-483.
• Ali MY, Zaib S, Rahman MM, et al. Didymin, a dietary citrus flavonoid exhibits anti-diabetic complications and promotes glucose uptake through the activation of PI3K/Akt signaling pathway in insulin-resistant HepG2 cells. Chem Biol Interact. 2019;305:180-194.
• Frontiers in Immunology. Didymin Suppresses Microglia Pyroptosis and Neuroinflammation Through the Asc/Caspase-1/GSDMD Pathway Following Experimental Intracerebral Hemorrhage. 2022.
• PMC10762818. Didymin protects pancreatic beta cells by enhancing mitochondrial function in high-fat diet-induced impaired glucose tolerance. Diabetology & Metabolic Syndrome. 2024.
• PMC10731721. Didymin alleviates metabolic dysfunction-associated fatty liver disease (MAFLD) via the stimulation of Sirt1-mediated lipophagy and mitochondrial biogenesis.
• PMC9188374. Didymin Ameliorates Liver Fibrosis by Alleviating Endoplasmic Reticulum Stress and Glycerophospholipid Metabolism: Based on Transcriptomics and Metabolomics.
• ScienceDirect. Didymin ameliorates hepatic injury through inhibition of MAPK and NF-κB pathways by up-regulating RKIP expression.
• PMC6269808. Anxiolytic-Like and Antinociceptive Effects of 2(S)-Neoponcirin in Mice.
• PMC10046851. Potential Treatment Options for Neuroblastoma with Polyphenols through Anti-Proliferative and Apoptotic Mechanisms.
• PMC4346128. Total Flavonoids from Clinopodium chinense (Benth.) O. Ktze Protect against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo.
• Wikipedia. Isosakuranetin — structural relationship to didymin.
• MDPI Molecules. Recent Trends in Potential Therapeutic Applications of the Dietary Flavonoid Didymin. 2018;23(10):2547.